WASHINGTON, D.C.—Early October saw cancer informatics and digital pathology workflow solution provider Inspirata Inc. announce that it was collaborating with Elsevier to integrate Elsevier’s ExpertPath and ImmunoQuery diagnostic decision support tools into its Digital Pathology Cockpit and cloud-based telepathology Consultation Portal.
“This integration gives pathologists the ability to contextually launch Elsevier’s reference and decision support tools from within our Digital Pathology Cockpit,” says Inspirata’s executive vice president and founder, Dr. Mark Lloyd. “These types of tightly coupled integrations enable us to offer our clients a fully immersive cockpit that contains all of the relevant resources pathologists need right at their fingertips. By reducing the time they spend searching for and retrieving information from different sources and systems, we are giving our users more time for their patients.”
ExpertPath is an anatomic and clinical pathology online decision support tool that equips pathologists with the expert-based information needed for diagnosing complex or unusual cases, examining a case in an unfamiliar specialty area, teaching students and residents, preparing for a lecture, as well as taking part in or preparing for a tumor board. Content includes differential diagnosis lists, ancillary tests, image galleries and specimen-handling protocols. Based on its recent analysis of clinical decision support systems for the pathology and radiology industry, Frost & Sullivan recently recognized ExpertPath with the 2017 North America Technology Innovation Award.
ImmunoQuery is an evidence-based decision support system for immunohistochemistry that reportedly provides powerful meta-analysis and up-to-date references to aid in diagnosing cancer, determining the stage and grade of a tumor and identifying where in the patient’s body the cancer originated.
“We are excited to be working with an innovator like Inspirata,” says Karthik Krishnan, senior vice president and general manager of clinical reference for Elsevier. “Knowing that our proven diagnostic decision support tools are going to be more readily accessible as part of a diagnostic workflow is a win for pathologists and the patients they serve.”